换一批EMPEROR-reduced研究：恩格列净对心力衰竭心血管和肾脏结局影响的研究
EMPEROR-Reduced study: Cardiovascular and renal outcomes with empagliflozin in heart failure
摘要EMPEROR-Reduced研究是一项关于恩格列净对射血分数降低的心力衰竭（HFrEF）患者临床结局影响的临床试验。该研究共纳入3 730例合并或不合并2型糖尿病的慢性心力衰竭（心衰）患者。结果发现，在标准和优化的抗心衰药物治疗基础上，恩格列净较安慰剂可显著降低HFrEF患者心血管死亡或心衰住院的复合终点发生率，且具有良好的安全性。
更多相关知识
abstractsThe EMPEROR-Reduced study is a clinical trial on the effect of empagliflozin on clinical outcomes of patients with heart failure with reduced ejection fraction (HFrEF). The EMPEROR-Reduced study included 3 730 chronic heart failure patients with or without type 2 diabetes mellitus (T2DM). The result showed that based on the standardized and optimal medication of heart failure, patients in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group.
More相关知识
关键词
射血分数降低的心力衰竭恩格列净心血管死亡心力衰竭住院预后Heart failure with reduced ejection fractionEmpagliflozinCardiovascular deathHospitalization for heart failurePrognosis
栏目名称
DOI
10.3760/cma.j.cn101460-20200915-00095
发布时间
2020-09-15（万方平台首次上网日期，不代表论文的发表时间）
- 浏览1068
- 被引9
- 下载207
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
